Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular drug class specificity: beta-blockers.

Michael J Reiter1

  • 1University of Colorado Health Sciences Center, Denver, CO 80262, USA. Michael.Reiter@UCHSC.edu

Progress in Cardiovascular Diseases
|November 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leveraging prior knowledge in machine intelligence to improve lesion diagnosis for early cancer detection.

Medical physics·2025
Same author

A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation.

PloS one·2024
Same author

Exploring Dual-Energy CT Spectral Information for Machine Learning-Driven Lesion Diagnosis in Pre-Log Domain.

IEEE transactions on medical imaging·2023
Same author

Transpedicular-Transdiscal Cement Augmentation Treatment of Thoracolumbar Fusion Proximal Junctional Failure.

International journal of spine surgery·2019
Same author

The many faces of cirrhosis.

Abdominal radiology (New York)·2019
Same author

Postoperative CT of the Mandible Following Trauma: Review of Normal Appearances and Common Complications.

Academic radiology·2018
Same journal

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
Same journal

Lessons from ATTR-CM clinical trials: Progress, persistent disparities, and emerging treatment dilemmas.

Progress in cardiovascular diseases·2026
See all related articles

Beta-blockers are crucial cardiovascular drugs. While differences exist, evidence supports specific agents like carvedilol, metoprolol, and bisoprolol for mortality benefits in heart failure and post-infarction care.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-adrenergic blockers are widely prescribed cardiovascular medications.
  • Significant variations exist among available beta-blockers, but their clinical relevance is not fully elucidated.
  • Key differences relate to receptor specificity (beta1, beta2, alpha-adrenergic receptors).

Purpose of the Study:

  • To clarify the clinical relevance of differences among beta-blocker agents.
  • To guide the selection of appropriate beta-blockers and their dosages based on available evidence.
  • To review evidence for mortality benefits in specific cardiovascular conditions.

Main Methods:

  • Review of clinical trial data for various beta-blockers.
  • Analysis of receptor specificity and intrinsic sympathetic activity (ISA).

Related Experiment Videos

  • Evaluation of evidence for mortality benefit in post-infarction and heart failure settings.

    • Main Results:

    • Nonselective beta-blockers without ISA are recommended post-infarction.
    • Specific agents (propranolol, timolol, metoprolol, carvedilol) show mortality benefits post-infarction.
    • Metoprolol, bisoprolol, and carvedilol demonstrate mortality benefits in heart failure.
    • Carvedilol may offer a survival advantage, though not universally accepted.

    Conclusions:

    • Beta-blocker selection should be guided by trial data and patient-specific factors.
    • Extrapolating benefits across all similar beta-blockers is not advisable.
    • Individualized selection, considering contraindications and side effects, is crucial for optimal patient outcomes.